Category Archives: Cardiovascular Pharmacology

In mid-March of 2020, the coronavirus disease (COVID-19) tsunami began washing over New York City with terrifying force. Even though the virus had already overwhelmed Wuhan, China, and walloped northern Italy and Spain, its speed and devastation took New Yorkers by surprise. Continue reading →

Heart complications, including heart attacks, become more of a risk as we age. But why is this? A team of researchers from the University of South Florida Department of Surgery set out to find the answer to why we are more susceptible to heart disease as we get older Continue reading →

As mega deals slow, private capital becomes the driving force behind 2020 M&A M&A volumes more than doubled between 2005 and 2019. By comparison, 2020 has been a slow year, with a marked decline in deal activity and a sharp drop in overall deal value. Continue reading →

Acai berries: The Brazilian "superfruit" Acai berries are known for their striking deep purple hue. Their mild, not-sweet-at-all taste make them the perfect base for smoothie bowls topped with oats, coconut shavings, and other antioxidant-rich berries. Continue reading →

December 01, 2020 07:30 ET | Source: Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, will be presented at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) by John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, COSMIC-HF and GALACTIC-HF. CVCT is a global invitation-only meeting of opinion leaders across clinical research, industry and regulatory authorities Continue reading →

Currently, in the United States, two research groups carry out clinical tests evaluating treatment with fluoxetine and fluvoxamine in patients with covid-19 Photomontage: Jornal da USP Ouse of a class of drugs already used to treat anxiety and depression disorders, selective serotonin reuptake inhibitors (fluoxetine and fluvoxamine), has been shown to have the potential to inhibit inflammation caused by the SARS-CoV-2 virus and its replication, decreasing damage to the brain and other body tissues. Currently, two research groups carry out clinical tests evaluating treatment with fluoxetine and fluvoxamine in patients with covid-19, in the United States Continue reading →

CHAPEL HILL For space exploration to be successful, we need to understand and address underlying causes of health issues observed in astronauts who have spent extended periods of time away from Earth. These problems include loss of bone and muscle mass, immune dysfunction, and heart and liver problems. Using data collected from a number of different resources, a multidisciplinary team led by NASA scientists reports the discovery of a common but surprising thread that drives this damage: mitochondrial dysfunction. Continue reading →

A woman holds a small bottle labelled Coronavirus COVID-19 Vaccine. Continue reading →

Can a combination of chemical compounds in foods such as phycobilins and resveratrol, keto diet, novel cannabis plant extracts and steam inhalation therapy prevent and cure COVID-19? Continue reading →

November 06, 2020 07:30 ET | Source: Cytokinetics, Incorporated Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related to GALACTIC-HF Results on November 13, 2020 at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six presentations at the American Heart Association (AHA) Scientific Sessions 2020, taking place online from November 13, 2020 November 17, 2020, including the presentation of primary results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, in a Late Breaking Clinical Trial session, as well as five poster presentations Continue reading →